822 related articles for article (PubMed ID: 30442276)
41. Chinese time trade-off values for EQ-5D health states.
Liu GG; Wu H; Li M; Gao C; Luo N
Value Health; 2014 Jul; 17(5):597-604. PubMed ID: 25128053
[TBL] [Abstract][Full Text] [Related]
42. The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries.
Konerding U; Elkhuizen SG; Faubel R; Forte P; Malmström T; Pavi E; Janssen MF
Health Qual Life Outcomes; 2014 Dec; 12():181. PubMed ID: 25479769
[TBL] [Abstract][Full Text] [Related]
43. EQ-5D-Y Value Set for Germany.
Kreimeier S; Mott D; Ludwig K; Greiner W;
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
[TBL] [Abstract][Full Text] [Related]
44. EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories.
Kreimeier S; Åström M; Burström K; Egmar AC; Gusi N; Herdman M; Kind P; Perez-Sousa MA; Greiner W
Qual Life Res; 2019 Jul; 28(7):1951-1961. PubMed ID: 30739287
[TBL] [Abstract][Full Text] [Related]
45. Child health valuation protocol for a discrete choice experiment comparing paired comparison and kaizen tasks and estimating US EQ-5D-Y-3L values on an experience scale.
Jumamyradov M; Craig BM; Rivero-Arias O; Jakubczyk M
BMJ Open; 2023 Oct; 13(10):e077256. PubMed ID: 37879694
[TBL] [Abstract][Full Text] [Related]
46. In search of a 'pan-European value set'; application for EQ-5D-3L.
Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH
BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625
[TBL] [Abstract][Full Text] [Related]
47. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
Gandhi M; Rand K; Luo N
Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
[TBL] [Abstract][Full Text] [Related]
48. Efficient Designs for Valuation Studies That Use Time Tradeoff (TTO) Tasks to Map Latent Utilities from Discrete Choice Experiments to the Interval Scale: Selection of Health States for TTO Tasks.
Che M; Pullenayegum E
Med Decis Making; 2023 Apr; 43(3):387-396. PubMed ID: 36866604
[TBL] [Abstract][Full Text] [Related]
49. EQ-5D-Y Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M;
Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
[TBL] [Abstract][Full Text] [Related]
50. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
[TBL] [Abstract][Full Text] [Related]
51. Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology.
Lipman SA; Zhang L; Shah KK; Attema AE
Eur J Health Econ; 2023 Mar; 24(2):293-305. PubMed ID: 35596831
[TBL] [Abstract][Full Text] [Related]
52. Patient versus general population health state valuations: a case study of non-specific low back pain.
van Dongen JM; van denBerg B; Bekkering GE; van Tulder MW; Ostelo RWJG
Qual Life Res; 2017 Jun; 26(6):1627-1633. PubMed ID: 28155048
[TBL] [Abstract][Full Text] [Related]
53. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
[TBL] [Abstract][Full Text] [Related]
54. Measurement Properties of the Online EuroQol-5D-Youth Instrument in Children and Adolescents With Type 1 Diabetes Mellitus: Questionnaire Study.
Mayoral K; Rajmil L; Murillo M; Garin O; Pont A; Alonso J; Bel J; Perez J; Corripio R; Carreras G; Herrero J; Mengibar JM; Rodriguez-Arjona D; Ravens-Sieberer U; Raat H; Serra-Sutton V; Ferrer M
J Med Internet Res; 2019 Nov; 21(11):e14947. PubMed ID: 31714252
[TBL] [Abstract][Full Text] [Related]
55. Fighting to Breathe and Fighting for Health-Related Quality of Life: Measuring the Impact of Being Dependent on Technology for Breathing on the Child and Their Caregiver.
Verstraete J; Booth C; Booth J; Peer S; McGuire J; Kritzinger F; Gray T; Zibi N; Shabangu P; Zampoli M
Patient; 2024 Jan; 17(1):65-82. PubMed ID: 37991685
[TBL] [Abstract][Full Text] [Related]
56. Time Trade-Off Value Set for EQ-5D-3L Based on a Nationally Representative Chinese Population Survey.
Zhuo L; Xu L; Ye J; Sun S; Zhang Y; Burstrom K; Chen J
Value Health; 2018 Nov; 21(11):1330-1337. PubMed ID: 30442281
[TBL] [Abstract][Full Text] [Related]
57. An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L.
Khanna D; Khadka J; Mpundu-Kaambwa C; Chen G; Dalziel K; Devlin N; Ratcliffe J;
Pharmacoeconomics; 2024 Jun; 42(Suppl 1):113-128. PubMed ID: 38280125
[TBL] [Abstract][Full Text] [Related]
58. Concordance among Swedish, German, Danish, and UK EQ-5D-3L Value Sets: Analyses of Patient-Reported Outcomes in the Swedish Hip Arthroplasty Register.
Teni FS; Rolfson O; Berg J; Leidl R; Burström K
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575317
[No Abstract] [Full Text] [Related]
59. Patient-caregiver agreement and test-retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies.
Zhou W; Shen A; Yang Z; Wang P; Wu B; Herdman M; Luo N
Eur J Health Econ; 2021 Sep; 22(7):1103-1113. PubMed ID: 33950465
[TBL] [Abstract][Full Text] [Related]
60. Health-related quality of life in residents aged 18 years and older with and without disease: findings from the First Provincial Health Services Survey of Hunan, China.
Deng X; Dong P; Zhang L; Tian D; Zhang L; Zhang W; Li L; Deng J; Ning P; Hu G
BMJ Open; 2017 Sep; 7(9):e015880. PubMed ID: 28871016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
